United States Antibiogram: Difference between revisions

No edit summary
No edit summary
Line 54: Line 54:
|-
|-
|}
|}
==Key==
*+ usually effective clinically or >60% susceptible
*+/- clinical trials lacking or 30-60% susceptible
*0 not effective clinically or <30% susceptible
*blank data not available


==See Also==
==See Also==

Revision as of 06:56, 5 February 2014

Organisms Penicillins Anti-Staphylocccal Penicillins Amino-Penicillins Anti-Pseudomonal Penicillins Carbapenems Aztreonam Fluroquinolones
Penicillin G Penicillin V Methicillin Nafcillin/Oxacillin Cloxacillin/Diclox. AMP/Amox Amox/Clav AMP-Sulb Ticarcillin Ticar-Clav Pip-Taxo Piperacillin Doripenem Ertapenem Imipenem Meropenem Aztreonam Ciprofloxacin Ofloxacin Pefloxacin Levofloxacin Moxifloxacin Gemifloxacin Gatifloxacin
Strep, Group A, B, C, G + + + + + + + + + + + + + + + + 0 +/- +/- 0 + + + +
Strep. pneumoniae + + + + + + + + + + + + + + + + 0 +/- +/- 0 + + + +
Viridans strep +/- +/- +/- +/- +/- +/- +/- +/- +/- +/- +/- +/- + + + + 0 0 0 + + + +
Strep. milleri + + + + + + + + + + + + + + + + 0 0 0 + + + +
Enterococcus faecalis + + 0 0 0 + + + +/- +/- + + +/- 0 + +/- 0 ^^ ^^ 0 + + + +
Enterococcus faecium +/- +/- 0 0 0 + + + +/- +/- +/- +/- 0 0 +/- 0 0 0 0 0 0 +/- +/- +/-
Staph. aureus (MSSA) 0 0 + + + 0 + + 0 + + 0 + + + + 0 + + + + + + +
Staph. aureus (MRSA) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/- +/- +/-
Staph. aureus (CA-MRSA) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 +/- +/- +/- +/- +/-
Staph. epidermidis 0 0 + + + 0 0 0 +/- +/- + 0 + + + + 0 + + + + + + +
C. jeikeium 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L. monocytogenes + 0 0 0 0 + + + '+ + +/- + + 0 + 0 0 + + + +

Key

  • + usually effective clinically or >60% susceptible
  • +/- clinical trials lacking or 30-60% susceptible
  • 0 not effective clinically or <30% susceptible
  • blank data not available

See Also

Source

Sanford Guide to Antimicrobial Therapy 2010 | Example || Example || Example |}